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ABSTRACT ÖZET
Objective: To explore the HBV and HCV seroprevalence rates among 
pregnant women attending the Obstetric Outpatient Unit at the 
Medical Faculty of Zonguldak Bülent Ecevit University and to 
provide contributory data to the already existing data from the other 
geographical regions of Turkey.
Materials and Methods: HBsAg, anti-HBs and anti-HCV seropositivity 
rates were retrospectively investigated among a total of 1084 
pregnant women attending the Obstetric Outpatient Unit at the 
Medical Faculty of Zonguldak Bülent Ecevit University between 
January 2012 and January 2014 Serum assays were performed 
using a chemiluminescence immunoassay method according 
the manufacturer’s instructions (Cobas e 411 Analyzer, Roche 
Diagnostics, Mannheim, Germany). Statistical analyses of the study 
data were performed using SPSS 18.0 software package (SPSS Inc., 
Chicago IL, USA).
Results: The mean age of the 1084 pregnant participants was 
29.12±5.48 years (min: 17, max: 46 y) and the average gestational 
age was 10.7±4.64 weeks. HBsAg, anti-HBs, and anti-HCV detection 
rates were 4% (n=43), 7.3% (n=79), and 0.6% (n=7), respectively. 
With regard to age groups, HBsAg was positive in 3.1%, 3.7%, 
4.4%, and 5.9% of the women who were below 20 years of age, 
between 21 and 30 years of age, between 31 and 40 years of age, 
and over 40 years of age, respectively. 
Conclusion: While similar rates of seroprevalence for HBsAg and 
anti-HCV were found as compared to the previous reports from 
Turkey, anti-HBs positivity rates were lower than that in most of the 
previous reports.
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Amaç: Bu çalışmada, Zonguldak Bülent Ecevit Üniversitesi Tıp 
Fakültesi Hastanesi, kadın Hastalıkları ve Doğum kliniğine başvuran 
gebelerde HBV ve HCV seroprevalans oranlarının araştırılması ve elde 
edilen oranların ülkemizin farklı yerlerindeki oranlarla karşılaştırılarak 
ülkemiz verilerine katkı sağlanması amaçlanmıştır. 
Gereç ve Yöntemler: Bülent Ecevit Üniversitesi Tıp Fakültesi kadın 
Hastalıkları Doğum kliniğine Ocak 2012-Ocak 2014 tarihleri 
arasında başvuran 1800 gebenin HBsAg, anti-HBs ve anti-HCV 
seropozitiflik oranları retrosektif olarak incelenmiştir. Verileri yeterli 
olan 1084 gebe çalışmaya dahil edilmiştir. Hastaların serumları 
kemilümünesans immünassay yöntemi ile üretici firmanın (Cobas e 
411 Analyzer, Roche Diagnostics, Mannheim, Germany) önerilerine 
göre çalışılmıştır. Elde edilen veriler SPSS 18.0 (SPSS Inc., Chicago 
IL, USA) paket programı kullanılarak istatiksel değerlendirilmesi 
yapılmıştır.
Bulgular: Çalışmaya alınan 1084 gebenin yaş ortalaması 29,12±5,48 
(min: 17, max: 46), ortalama gebelik haftası 10,7±4,64 idi. HBsAg 
pozitifliği %4 (n=43), anti-HBs %7,3 (n=79), anti-HCV %0,6 (n=7) 
oranında bulunmuştur. HBsAg pozitifliği 20 yaş altında %3,1, 21-30 
yaş arası %3,7, 31-40 yaş arası %4,4, 40 yaş üstü ise %5,9 olarak 
saptandı. 
Sonuç: Sonuç olarak çalışmamızda HBsAg ve anti-HCV seroprevalansı 
ülkemizde yapılan diğer çalışmalarla benzer oranda bulunurken, anti-
HBs pozitifliği ise bazı çalışmalar ile benzer sonuçlarda olsada, birçok 
çalışmaya göre düşük oranda saptanmıştır.
Anahtar Kelimeler: HBV, HCV, seroprevalans, gebelik, doğum öncesi 
takip
Çıkar çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar 
çatışması bildirmemişlerdir.
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Introduction
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections 
represent major public health problems both in Turkey and globally 
(1). More than 2 billion people have been infected with HBV 
and approximately 350–400 million of them have chronic HBV 
infection. Turkey has intermediate endemicity of HBV infection 
with the prevalence varying between 2 and 7% (2,3). HBV infection 
may occur via parenteral or percutaneous routes; horizontal 
transmission through mucosal contact with infected blood or bodily 
secretions and vertical transmission during the perinatal period (4). 
Perinatal transmission accounts for 40-50% of HBsAg carriers. On 
the other hand, HBeAg positivity increases the transmission rate 
from mothers to newborns, with approximately 90% of infants 
who acquire HBV infection from their mothers at birth become 
chronically infected (5). 
Nearly 170 million individuals worldwide are infected with 
HCV, and 1 to 3% of the Turkish population has been found to be 
infected with HCV (6). Although parenteral route is the principal 
form of the transmission, vertical transmission has also been 
reported (7). Transmission risk of HCV from infected pregnant 
women to their infant is 2-8% (8). Therefore, screening pregnant 
women for HBV and HCV is of great importance in preventing 
mother-to-child transmission. The seropositivity rates for HBsAg 
and anti-HCV in a group of women attending to the Obstetric 
Outpatient Unit was similar to that previously reported in Turkey. 
However, despite similarities with some previous figures, anti-HBs 
positivity rates were lower than that reported by the majority of 
other studies. In this study, our objective was to examine the 
HBV and HCV seroprevalence in pregnant women attending our 
unit and to compare our findings with that of previous reports to 
contribute to the existing national data. 
Materials and Methods
HBsAg, anti-HBs and anti-HCV seropositivity rates were 
retrospectively examined among a total of 1800 pregnant women 
who attended the obstetrics outpatient clinics at the Medical 
Faculty of Zonguldak Bülent Ecevit University between January 
2012 and January 2014. 
The data of 1084 pregnant women were deemed adequate for 
inclusion. Serum assays were performed using a chemiluminescence 
immunoassay method according the manufacturer’s instructions 
(Cobas e 411 Analyzer, Roche Diagnostics, Mannheim, Germany). 
Statistical analyses of the data were performed using SPSS 18.0 
software package (SPSS Inc, Chicago IL, USA).
Results
The mean age of the 1084 participants was 29.12±5.48 
years (min: 17, max: 46 y) and the average gestational age was 
10.7±4.64 weeks. HBsAg, anti-HBs, and anti-HCV detection rates 
were 4% (n=43), 7% (n=79), and 0.6% (n=7), respectively (Table 
1). HBsAg was positive in 3%, 4%, 4%, and 6% of the women 
who were below 20 years of age, between 21 and 30 years of 
age, between 31 and 40 years of age, and over 40 years of age, 
respectively. Anti-HCV and anti-HBs positivity rates in different age 
groups are shown in Table 2. 
 
Discussion
HBV and HCV infections are the leading causes of cirrhosis, liver 
failure, and hepatocellular carcinoma (9). The reported prevalence of 
chronic HBV infection in the Turkish population ranges between 
3% and 12.5% and transmission of the virus from HBsAg-positive 
mothers to newborns represents an important route for disease 
spread (10). Due to the high incidence of HBsAg positivity among 
pregnant women both in Turkey and in other countries, screening 
tests are very important for public health. The reported HBsAg 
positivity among Turkish pregnant women for the time period 
between 1987 and 2004 varies between 3.5% and 9.3% (11). The 
reported HBsAg prevalence rates from different countries exhibit 
significant variability, probably due to the influence of a number of 
factors including age, occupation, socio-economical status, IV drug 
use, blood transfusion, or sexual intercourse (12). For instance, a 
seropositivity rate of 10.8% for HBsAg has been detected among 
pregnant women in Yemen, however, screening of antenatal 
women is not routine in this country (13). A Nigerien study found a 
remarkably high incidence of HBsAg positivity, i.e. 16.6%, among 
pregnant women, and the authors emphasized the importance of 
screening of pregnant women and vaccination of the newborns 
(14). In contrast with the respective prevalence rates of 4.6% (15), 
2.9% (16), and 1.9% (17) in Nigeria, India and Bali, the reported 
Table 2. Distribution of HBsAg, anti-HBs and anti-HCV positivity in age groups
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Table 1. HBsAg, anti-HBs, and anti-HCV seropositivity rates in pregnant 
women 
HBsAg Anti-HBs Anti-HCV
 n ( %) n (%)  n (%)
Positive 43 (4) 79 (7) 7 (0.6)
Negative 1041 (96) 1005 (93) 1077 (99.4)
Total 1084 (100) 1084 (100) 1084 (100)
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figures from Spain, Brazil, Peru, Ireland and North Italy are relatively 
lower, i.e. 0.4% (18), 0.5 (19) and 0.7% (20), 0.6% (21), 0.7% (22), 
and 1% (23), respectively. The figures in our study (i.e. 4%) are 
similar to those reported from Nigeria. 
Previous studies from our country on the HBsAg and anti-HBs 
seropositivity rates display some degree of variability. Çopur Çiçek 
et al., reported anti-HBs prevalence of 25% in their study with 
one of the largest study samples that included a total of 56.275 
pregnant women from Şanlıurfa (4). On the other hand, kuru et 
al. detected a HBsAg prevalence of 4.2% in an Istanbul sample 
consisting of 5366 pregnant women (24). Similarly, in another 
study from İstanbul by Saveci, HBsAg and anti-HBs seroprevalence 
rates were 1.52% and 17.7%, respectively (25). The prevalence 
of HBsAg and anti-HBs reported by kölgelier et al. (26) from 
Adıyaman were 4.7% and 37.4%, respectively. The corresponding 
figures from kırıkkale by Sağsöz et al. (27) were 4.9% and 26.4%, 
from Denizli by kaleli et al. (28) were 7.6% and 22.75%, and from 
Afyon by Yılmazer et al. (29) were 2.9% and 18.4%. Also, Tosun et 
al. (30) reported a HBsAg positivity of 6.2% from Manisa province. 
Additionally, the figures reported by Coskun et al. (31) from Istanbul 
were 3.6% and 8.6%, and from kocaeli by Çakmak et al. (32) were 
2.2% and 3.7%, respectively. In our study, of the participating 
pregnant women, 4% were seropositive for HBsAg and 7.3% 
were seropositive for anti-HBs. Despite a similarity to previous 
reports in terms of HBsAg prevalence, except for some studies, the 
rate of anti-HBs positivity in our sample was lower as compared to 
the national average. 
With regard to anti-HCV seropositivity rates, a significant 
variability in the reported figures can be noted. In studies involving 
pregnant women from India, Mali, Brazil, Spain, Switzerland, 
Puerto-Rico, and England the reported prevalence was less than 
1% (16,18,20,33). On the other hand, the corresponding figures 
were 3.2%, 5.3%, and 5.4% in Pakistan, Malawi, and Burkina 
Faso, respectively (34). Similar to previous studies from Turkey, the 
observed anti-HCV seroprevalence was 0.6% in our study. The 
reported rates by Çopur Çiçek et al. (4), kölgelier et al. (26), Coşkun 
et al. (31), Çakmak et al. (32), Gönen (35), Atılgan et al. (36), and 
kurdoğlu et al. (37) were 0.8%, 0.2%, 0.7%, 0.3%, 0.3%, 0,44%, 
and 0,54%, respectively. Conversely, karaca et al. and Gül et al. 
reported slightly higher figures, i.e. 1.3% and 2.4%, respectively. 
On the other hand, seroprevalence of 0% was reported by 
Yılmazer et al. (29) and by Yücel et al. (4). 
In conclusion, HBsAg and anti-HCV seroprevalence rates 
observed in this study were generally in line with previously 
reported figures from Turkey. On the other hand, the seroprevalence 
for anti-HBs was lower than in most other studies except for a 
few of them. This may be due to inadequate vaccination among 
women of reproductive age in Zonguldak area. Routine screening 
tests should be offered to all pregnant women with vaccination of 
those who are seronegative, and with appropriate administration of 
immunoglobulins and vaccines at the time of birth for those women 
who are HBsAg seropositive. Educational activities particularly 
focusing on those with a pre-marriage HBsAg positivity, provision 
of information on future partners regarding protection methods, 
and encouraging vaccination in those with anti-HBs negativity are 
important preventive targets. 
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